CalciMedica, Inc. (CALC) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は La Jolla, CA, アメリカ. 現CEOは A. Rachel Leheny.
CALC を有する IPO日 2023-06-14, 14 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $10M.
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
